Clinical Design and Objectives

A multicenter, randomized, double‑blind, parallel‑group Phase 1 study will be conducted. The trial aims to determine whether HLX17 is pharmacokinetically and immunogenically equivalent to the U.S.-originated Keytruda. Development of a biosimilar represents a strategic effort to reduce the high cost of existing anti‑PD‑1 antibodies and broaden patient access.

Patient Population and Indications

Patients who have undergone complete resection for non‑small cell lung cancer (NSCLC), melanoma (MEL), or renal cell carcinoma (RCC) will be enrolled. These solid tumors demonstrate high response rates to immune‑checkpoint inhibition, yet the risk of recurrence remains. Enrolling resected patients enables early assessment of adjuvant therapeutic benefit.

Key Endpoints

The primary endpoints include PK profile, efficacy, safety, and immunogenicity. PK will be evaluated by comparing serum concentrations and half‑life to assess biological equivalence, while immunogenicity will be monitored through anti‑drug antibody responses. Efficacy and safety are essential to confirm that HLX17 delivers comparable therapeutic benefit and adverse‑event profile to Keytruda.

Market and Industry Implications

If HLX17 demonstrates equivalence to Keytruda, it could become a cost‑effective alternative in China and other Asian markets. This may alter Merck’s revenue composition and accelerate competition among biosimilars. Investors should therefore monitor the R&D capabilities of Chinese biopharma firms and their strategies for entering global clinical programs.